Purpose: The purpose of this study was to develop a SIRT2-specific substrate-type radiotracer for non-invasive PET imaging of epigenetic regulatory processes mediated by SIRT2 in normal and disease tissues. Procedures: A library of compounds containing tert-butyloxycarbonyl-lysineaminomethylcoumarin backbone was derivatized with fluoroalkyl chains 3-16 carbons in length. SIRT2 most efficiently cleaved the myristoyl, followed by 12-fluorododecanoic and 10-fluorodecanoic groups (K cat /K m 716.5 ± 72.8, 615.4 ± 50.5, 269.5 ± 52.1/s mol, respectively glioma-bearing rats were discouraging, due to rapid defluorination of this radiotracer upon intravenous administration, as evidenced by significant accumulation of F-18 radioactivity in the skull and other bones, which confounded the interpretation of images of radiotracer accumulation within the tumor and other regions of the brain.
Introduction
Over the past two decades, epigenetic regulation has become a rapidly growing, highly innovative and influential field of biology and medicine. One key epigenetic regulatory mechanism involves acetylation and deacetylation of lysine residues of histone core proteins and other critical proteins involved in regulation of gene expression and cell function. Protein acetylation and deacetylation is mediated by histone acetylase transferases (HATs) and histone deacetylases (HDACs), respectively. There are currently 18 HDAC proteins identified in the human genome, which are subdivided into 4 main classes [1] . Classes I, II (a and b), and IV are Zn 2+ -dependent enzymes [2] and include HDACs 1-11, while class III is comprised of seven isoforms of NAD + -dependent HDAC enzymes. HDAC class III enzymes are termed the Bsilent information regulators^or Bsirtuins^(SIRTs), originating from the yeast SIR2 homologue, and consist of SIRT1-7 [1] . The SIRT isoforms vary in their cellular localization, with SIRTs 1, 6, and 7 being primarily located in the nucleus, SIRTs 3, 4, and 5 located in mitochondria. SIRT2 is primarily localized in the cytoplasm, but can translocate into the nucleus [3] and deacetylase of cytoplasmic alpha-tubulin and nuclear H4K16 proteins, thereby acting as a mitotic exit and cell cycle regulator [3] [4] [5] [6] [7] [8] .
Several studies have revealed important roles of SIRT2 in the pathogenesis of various diseases. SIRT2 can play a neuroprotective role in neuorodegenerative diseases, such as Parkinson's, Alzheimer's [9] , and Huntington's [10] . SIRT2 has been identified as having both cancer-promoting functions (i.e., through stabilization of Myc oncoproteins in breast cancer [11, 12] ), as well as cancer-suppressing functions (i.e., through tubulin regulation [4] ). Therefore, SIRT2 has been identified as a potential drug target for treatment of various neurodegenerative and inflammatory diseases and cancer. However, it is important to assess its activity during pharmacomodulation (i.e., activation or inhibition) due to pleiotropic roles of SIRT2 under normal and pathologic conditions. The development of non-invasive molecular imaging approaches for monitoring SIRT2 expression and activity in vivo using PET with SIRT2-selective substrate radiotracer may aid in the development of therapies targeting SIRT2.
Understanding structure-activity relationships (SAR) of SIRT2 and its endogenous substrates is important for the development of SIRT2-specific substrate-type radiotracers. The best-studied endogenous substrates of SIRT2 are acetyl-α-tubulin and acetyl-H4K16. SIRT2, similar to other SIRT isoforms namely 4, 5, and 6, is able to cleave larger moieties outside of the acetyl. In particular, it has been demonstrated that SIRT2 can cleave a myristoyl group from the myristoyl-(K19 and K20)TNFα [13] .
To explore the efficiency with which SIRT2 cleaves larger leaving groups, a focused library of potential substrates was synthesized with tert-butyloxycarbonyl-lysine-aminomethylcoumarin (Boc-Lys-AMC) backbone derivatized on the free amino terminus of lysine with a fluoroalkyl chain varying between 3 and 16 carbons in length. Additionally, the influence of fluorine substitution on the ω-carbon in the alkyl chain on substrate affinity and specificity for SIRT2 was evaluated as well. The library of compounds was studied using a fluorogenic enzyme assay with recombinant SIRT2 to determine trends in catalytic efficiency. Furthermore, the SAR of these compounds with SIRT2 was investigated using in silico modeling to better understand the observed trends ( Fig. S1 Electronic Supplementary Material (ESM)). Based on these studies, the lead compound, the Boc-Lys(12-fluorododecanoyl)-AMC, was identified and its analogue with an aminohexanoicanilide (AHA) backbone was synthesized (12- 18 F]DDAHA conducted in a 9L gliomabearing rats were discouraging, due to rapid defluorination of this radiotracer upon intravenous administration, as evidenced by significant accumulation of F-18 radioactivity in the skull and other bones, which confounded the interpretation of images of radiotracer accumulation within the tumor and other regions of the brain. Due to these observations, full characterization of this radiotracer in vivo (i.e., blocking studies) has not been performed. The next generation of SIRT2-specific radiotracers with reduced systemic defluorination should be developed using alternative sites of radiofluorination on the aliphatic chain of DDAHA (i.e., the 3-position).
Materials and Methods

Synthesis of ω-Fluorinated Acyl Chains
Details of chemical synthesis and analytical procedures can be found in Electronic Supplementary Materials (ESM) online.
Cell Cultures and In Vitro Radiotracer Uptake Studies
The U87MG, MCF-7, MDA-MB-435, and MiaPaca cell lines were used to demonstrate differential levels of 12-[ 18 F]DDAHA cellular accumulation. Further details can be found in ESM online.
Intracerebral Glioma Model in Rats
9L tumor cells were implanted into Sprague-Dawley rats and grown in vivo for development of a glioma-bearing rat model. Further details can be found in ESM online.
PET/CT/MR Imaging
PET imaging with 12-[
18 F]DDAHA was conducted in a similar manner as previously published [15] . Details can be found in the ESM online.
Histology and Immunohistochemistry
After the completion of in vivo imaging studies, animals were euthanized under anesthesia and the brain was extracted and prepared for immunohistochemical staining to visualize SIRT2 expression. Details can be found in ESM online.
Results
The library of compounds with terminally fluorinated acyl chains was synthesized through traditional coupling methods of the fluorinated carboxylic acid chain with the lysine amino derivative via in-situ formation of an acetyl chloride in moderate yields of 20-55 %. Synthesis of the fluorinated carboxylic acid chains employed a novel approach: diethylaminosulfur trifluoride was used for non-selective fluorination of the n-hydroxycarboxylic acid forming the acetyl fluoride and fluorination of the terminal carbon. Selective hydrolysis of the acetyl fluoride was achieved using flash chromatography over silica gel to form a mono-ω-fluorinated chain due to the abrupt change in pH. The purity of final compounds in the library was 9 95 %, as determined by 1 H-NMR, 13 C-NMR, 19 F-NMR, and HRMS (Fig. 1a) .
Compound 7 was synthesized from Cbz-Lys-OH (Bachem) and Boc-Lys-AMC (Bachem), which was d e r i v a t i z e d t o B oc -L y s ( m y r ) -A M C . F o l l o w i n g myristoylation, the Boc protecting group was removed and the resulting free lysine amino terminus was coupled with the Cbz-Lys-OH group. The four-step synthesis yielded 7 in a yield of 12 % with 9 95 % purity as determined by 1 H-NMR, 13 C-NMR, and HRMS (Fig. 1b) . 18 F]DDAHA (11) was performed using a brominated precursor, 12Br-DDAHA (9); however, due to low radiochemical yield, the iodinated precursor, 12I-DDAHA (10), was used for optimization of the radiolabeling procedure and improvement of radiosynthetic yield. The iodinated precursor (10) was synthesized from the brominated precursor in a high yield of 73 % using literature procedure [19] . The radiochemical yield achieved with precursor 10 was 5-fold higher than that with precursor 9. The highest radiofluorination yields were achieved using precursor 10 in acetonitrile at 85-90°C. 12-[ 18 F]DDAHA was obtained with purity of 9 95 % (Fig. 1d , and S3 ESM) and a decay-corrected radiochemical yield of 12 % (total preparation time 66 min) with specific activity of 259 GBq/mmol.
Biochemical Characterization
Results from in vitro characterization of this library of compounds using fluorogenic assay demonstrated a positive correlation between the substrate efficiency for SIRT2 and the increasing length of the leaving alkyl chain. Compound 5 containing the myristoyl group was the most efficient substrate of SIRT2 with K cat /K m = 715.6 ± 72.8/s mol followed by compound 4 (fluorododecanoyl) and compound 3 (fluorodecanoyl) with K cat /K m of 615.4 ± 50.5/s mol and 269.5 ± 52.1/s mol, respectively. In contrast, compound 6 containing the fluoropalmitoyl leaving group exhibited a significant decrease in substrate efficiency for SIRT2 (30.4 ± 7.3/s mol), as compared to compounds containing shorter fluoroalkyl chains. The reference substrate, p53(379-382)K382ac-AMC (BPS1) exhibited K cat /K m = 275 ± 42/s mol (Fig. 2 , Table 1 ).
To assess the influence of a Bcap^modification on SIRT2 selectivity, compounds 4, 5, and 7 were evaluated against a panel of recombinant sirtuins (SIRT1-7). Compound 7 was cleaved efficiently by SIRT2, SIRT3, and, to a lesser extent, by SIRT6. In contrast, 4 and 5 were cleaved efficiently only by SIRT2 (Fig. S2 ESM) . To validate the substrate efficiency of 4 with SIRT2, a competitive inhibition assay with AGK2 (SIRT2-specific inhibitor) was performed, which yielded an IC 50 of 28.21 μmol of AGK2 (Fig. S2 ESM) .
In Silico Modeling
In silico modeling studies demonstrated that positioning of compounds 4 and 5 in the SIRT2 active site resulted in a smaller distance between the carbonyl carbon and the nicotinamide-ribose ester linkage ( Fig. S4a and S4b ESM). This may contribute to enhanced substrate efficiency of these compounds. (Fig. 3) , as compared to U87MG 9 MiaPaCa 9 MCF10A cells, which are known to express lower levels of SIRT2 [20] (very low levels of SIRT2 in U87 reported in Maxwell, et al. 2011 [21] ). The extracellular-to-intracellular radioactivity concentration equilibrium was achieved in about 1 min of incubation with 12- tracer derived-radioactivity accumulation and retention within the tumor versus normal brain structures between 15 and 20 min post i.v. administration (Fig. 4) . However, interpretation of PET/CT/MR images of [ 18 F]-12-DDFAHAderived radioactivity accumulation in 9L gliomas and in the brain cortex was challenging due to high levels of radioactivity accumulation in the adjacent scull bones, which created Bspillover^artifacts (Fig. 4b, c) . High levels of radioactivity in the bone were caused by rapid defluorination of [ 18 F]-12-DDFAHA after i.v. administration. To reduce the appearance of bone radioactivity-causing artifacts in brain PET images, we used the NIH + white (max) lookup table for color coding the range of radioactivity concentrations in the images (Fig. 4d) .
Immunohistochemical Validation of SIRT2 Expression in 9L Glioma and Normal Brain Structures
Fluorescence microscopy of sections of rat brains revealed heterogeneously distributed patchy appearing circularshaped regions of SIRT2 expression in 9L gliomas (Fig. 5a,  b) , as well as in the peripheral infiltrating zones.
Immunihistochemical staining for HIF-1a expression in adjacent tissue sections confirmed that the areas of reduced SIRT2 expression in tumors co-localized with areas of increased HIF-1a expression (Fig. 5c, d ). In the cerebral cortex, SIRT2 expression was expressed mainly in the neurons, with the highest concentrations in perinuclear regions of pyramidal neurons and lower levels in the axons (Fig. 5e, f) . In the hippocampus, the level of SIRT2 expression was highest in CA2 and CA3 neurons and had a similar sub-cellular perinuclear localization pattern, as in cortical neurons (Fig. 5g, h ). In the cerebellum, SIRT2 was strongly overexpressed in Purkinje cells, with perinuclear localization stronger than in cortical and hippocampal neurons; SIRT2 was also observed in neurons in the molecular layer at somewhat lower levels of expression than in Purkinje cells, but was almost entirely absent in the granular layer neurons (Fig. 5i, j) .
Discussion
To develop the first-generation substrate-type radiotracer selective to SIRT2, it was necessary to understand the structure-activity relationships of SIRT2 with various natural Fig. 2 . Biochemical assay data from Fluor de Lys assay®. a The catalytic efficiency (K cat /K m ) for SIRT2 against different length fluoroalkyl chain leaving groups to assess the structure activity relationship between these compounds and SIRT2. The error bars represent the standard deviation of N = 6 experiments. These values were taken from 15-min incubation to capture linear phase kinetics. b Compound 7 is not selective for SIRT2 whereas compounds 4 and 5 are selective for SIRT2. These results were taken from 40-min incubation of substrate with enzyme. The error bars represent the standard deviations of the means with significance of P G 0.05 denoted by *, as determined by two-way ANOVA. c The table details the effect on K m (amount of substrate necessary for half of V max ), V max (the maximal turnover velocity for a given substrate in SIRT2), and K cat (the catalytic efficiency for a given substrate with SIRT2). This data is determined in linear phase kinetics of SIRT2 with 15-min of incubation; therefore, this data is slightly different than the values in Fig. 2b . and synthetic substrates. Previously, it has been reported that in addition to an acetyl group, SIRT2 can also cleave long acyl chains from lysine residues, including a myristoyl moiety [22] . Other HDAC class III enzymes, such as SIRT3 and SIRT6, have also been reported to cleave myristoylated lysines of the H3K9 peptide [23, 24] and K19-20TNF-α [22] . However, there are no data on the effects of fluorine substitution on the ω-carbon in alkyl chains on different lengths on SIRT2 catalytic efficiency. Our current studies demonstrate that catalytic efficiency of SIRT2 gradually increases with the elongation of fluoroalkyl chain from 3 to 12 carbons. The catalytic efficiency of SIRT2 for fluorododecanoyl chain (K cat /K m = 615.4 ± 50.5/s mol) is comparable (difference is not statistically significant) with that of the non-fluorinated myristoyl chain (reference compound, BPS1), which is cleaved most efficiently (K cat /K m = 716.5 ± 72.8/s mol). In contrast, the catalytic efficiency of SIRT2 was significantly lower for the fluoropalmitoyl group (K cat /K m = 60.4 ± 7.3/s mol). These observations agree with previous reports, demonstrating a similar trend in SIRT2 catalytic efficiency for the H3K9 peptide backbone derivatized with hexanoyl, octanoyl, decanoyl, dodecanoyl, and myristoyl groups, but significantly less efficiently the palmitoyl and lipoyl-derivatized H3K9 peptide [23, 24] . Similarly, using TNF-α peptide backbone with varying chain lengths to a fluorophore or quencher moiety the longer chain length (11 carbons) resulted in much improved catalytic efficiency over the shorter (6 or 8 carbons) or very long (13 carbons) chain lengths [25] . However, despite the similarities in trends, the absolute K cat /K m values obtained in the current study for different alkyl chains with Boc-Lys-AMC backbone are significantly lower than those reported previously using a H3K9 or TNF-α peptide [23] [24] [25] , which can be explained, at least in part, by the higher binding efficiency of a peptide Bcap^group, as compared to Boc-Lys-AMC. Similarly, reports of a Bcap^group containing either p53 or TNF-α peptide residues on one side and an AMC group on the other demonstrate reduced K cat /K m as compared to compounds with a full peptide cap [23, 25, 26] . Also, the observed differences may be due to the presence of electronegative ω-terminal fluorine. In the current study, the K cat /K m values were determined by measuring the rate of the AMC cleavage product formation [26] , whereas in some of the previously reported data, K cat /K m values were determined by measuring the rate of NAD + consumption, which may also explain the differences in absolute K cat /K m values between studies [23] .
To examine the selectivity of compounds for SIRT2 among all SIRT enzymes, three of the most efficient substrates, 4, 5, and 7 were screened against a panel of recombinant SIRT enzymes (SIRT1-7). The aim was to elucidate the differences in SIRT selectivity that may occur as a result of altering the cap (mono-vs di-lysine cap), the leaving group (12-vs 14-carbon chain), and last the terminal fluorine atom (12F-carbon vs 14-carbon). Our results indicate that compound 7, with a di-lysine cap, was cleaved more effectively by SIRT3 and SIRT6 than compound 5, with a mono-lysine cap. Therefore, 5 is more selective to SIRT2 as it shows very little cleavage by other SIRT enzymes. Both 4 (12F-carbon chain) and 5 (14-carbon chain) are cleaved effectively by SIRT2 and not by any other SIRT enzymes, indicating that both leaving groups are selective for SIRT2. These findings are consistent with other reports in the literature [22, 24, 27] and demonstrate that leaving group specificity may not entirely define the selectivity of a substrate to a certain SIRT enzyme. Altering the cap group can have a significant impact on the efficiency with which the SIRT enzyme cleaves a substrate.
Also, we assessed the effectiveness of the lead compound 4 as a synthetic substrate for SIRT2 using a potent selective SIRT2 inhibitor AGK2 [28] . A competitive inhibition study [28] was performed using increasing concentrations of AGK2 with 4 at its apparent K m concentration (8 μM) for SIRT2. The observed inhibition of SIRT2 by AGK2 at IC 50 of 28.21 μM using 4 as substrate was comparable to previously reported IC 50 values of 3-5 μM obtained with myristoylated or acetylated substrates of SIRT2 [29, 30] . As demonstrated by the comparable catalytic efficiencies of 4 and BPS1 (p53 (379-382)K382ac-AMC) this data further confirm that 4 is an efficient substrate of SIRT2.
Based on the results of biochemical and in silico modeling studies (additional discussion can be found in Supplemental Materials), we have chosen the dodecanoyl chain fluorinated on the ω-position for coupling to an AHA backbone (Fig. S2 ESM) Lys(myristoyl)-AMC as selective substrate for SIRT2 and because radiotracers with smaller molecular weight have pharmacokinetic advantages over radiotracers with larger molecular weight. The AHA backbone was chosen to increase the lipophilicity of the radiotracer and permeability across cell membranes, which would not be possible with a larger peptidic backbone. Accordingly, the radiotracer 12-[
18 F]DDAHA has a cLogP value of 5.32 indicating a strong ability to passively cross the cell membrane in and out of the cell. While the change in Bcap^group may alter the selectivity to SIRT2, it has a lesser effect on the catalytic efficiency, as this is determined largely by the leaving group structure rather than the cap group. Nevertheless, the synthesis and evaluation of these compounds are currently underway and will be reported separately. For synthesis of 12-[ 18 F]DDAHA, we adapted methods for radiolabeling of ω-[
18 F]substituted long-chain fatty acids [19] that are used for PET imaging of cardiac metabolism [31] . Our studies confirmed previous reports that ω-iodinated dodecanoyl precursor provides a 3-fold higher radiosynthetic yield than the ω-brominated precursor [19] . The radiosynthetic yield for 12-[
18 F]DDAHA could be optimized further by using microwave-assisted heating [19] .
In vitro radiotracer uptake studies in cell lines with varying degrees of SIRT2 expression provided initial 18 F]DDAHA-derived radioactivity accumulation was significantly increased in MDA-MB-435 melanoma and MCF-7 breast adenocarcinoma and to a much lesser degree, in U87MG glioma, as compared to MiaPaCa pancreatic carcinoma and MCF10A immortalized breast epithelial cells. MCF-7 cells are known to have increased SIRT2 expression [20, 32] . Also, MiaPaCa cells have demonstrated increased levels of SIRT2 expression via Western blot analysis [11] . The non-tumorigenic epithelial cells, MCF10A, exhibit significantly lower levels of SIRT2 expression [20] and served as a lower-expressing control for this study. These results indicate levels of 12-[
18 F]DDAHA-derived radioactivity accumulation correspond to levels of SIRT2 expression as reported elsewhere for MCF-7, MDA-MB-435, U87MG, MiaPaCa, and MCF10A cell lines.
Despite the high lipophilicity of the fluoroalkyl leaving group, the mechanism of substrate cleavage by SIRT enzymes allows for a radioactive leaving group to be entrapped in the cell, at least transiently. Specifically, SIRT2 enzymatic cleavage mechanism results in formation of an ester linkage between the alkyl leaving group and O-ADPR (Fig. S1 ESM) , resulting in 18 F-fluoroalkyl-O-ADPR product which cannot cross a cell membrane because it is quite large and very polar (containing 2 negatively charged phosphate groups) (Fig. S1 ESM) . Therefore, SIRT2-mediated cleavage of 18 Furthermore, our initial in vivo PET imaging studies using 12-[
18 F]DDAHA conducted in a 9L glioma-bearing rats were discouraging, due to rapid systemic defluorination of this radiotracer upon intravenous administration. This was evidenced by significant accumulation of F-18 radioactivity in the skull and other bones, which confounded the interpretation of images of radiotracer accumulation within the tumor and other regions of the brain. Therefore, additional PET/CT MR images in panel Fig. 4d are shown in NIH + white (max) look-up (Fig. 4) . Progressive accumulation of 12-[
18 F]DDAHA-derived radioactivity in normal brain structures with high levels of SIRT2 expression and especially in 9L tumor lesions (Fig. 4) 18 F]DDAHA upon intravenous administration, a more complete characterization of this radiotracer in vivo (i.e., blocking studies) has not been performed.
To validate the results of PET/CT/MR imaging with 12-[ 18 F]DDAHA and to assess the cell specificity and heterogeneity of SIRT2 expression-activity in 9L gliomas and in different brain structures, we used immunofluorescent microscopy (IFM) in 9L glioma-bearing rat brain tissue sections. Fluorescence microscopy of tissue sections of intracerebral 9L gliomas growing in the rat brains stained with anti-SIRT2 fluorescent antibodies revealed heterogeneously distributed patchy-appearing circular regions of SIRT2 expression in core regions in peripheral infiltrating zones of 9L gliomas. Such pattern of expression suggested that SIRT2 is upregulated in well-perfused regions of 9L gliomas, whereas the expression of SIRT2 in hypoxicappearing regions is significantly reduced, which was confirmed immunohistochemically by presence of HIF-1α expression in the same regions in adjacent tissue sections. These results are consistent with previous reports of regulatory loops of HIF-1a-SIRT2, involving HIF-1α-mediated transcriptional repression of SIRT2 expression [35] , as well as SIRT2-mediated deacetylation of Lys709, which increases prolyl-hydroxylase binding and ubiquitinmediated degradation of HIF-1α [36] .
In the normal brain structures, the highest level of SIRT2 expression was observed in hippocampal CA2 and CA3 neurons, followed by pyramidal neurons in cerebral cortex, and cerebellar Purkinje cells. The subcellular localization of SIRT2 was predominantly perinuclear with lower levels of diffuse distribution in the rest of the neuronal cytoplasm and axons. These observations of neuronal-specific subcellular localization of SIRT2 in the brain are in agreement with previous reports [21] which demonstrated that SIRT2 expression in the murine brain is higher in hippocampal CA2-3 neurons, cortical neurons, and in cerebellar Purkinje cells and molecular layer neurons, but not in the granular layer neurons or other cells of oligedendroglial lineage. Thus, in situ microscopy results can serve as the basis for interpretation of in vivo PET/CT/MRI images and confirm that the increased levels of radiotracer accumulation in intracerebral 9L gliomas and in certain normal brain structures are mediated by increased SIRT2 expressionactivity levels, as compared to other brain structures expressing lower levels of SIRT2.
Also, this study provides grounds for development of the next generation of SIRT2-specific radiotracers. Several previous studies have reported defluorination of ω-[ 18 F]substituted fatty acids in rodents following intravenous injection [31] but significantly lower levels of defluorination occurred in higher order mammals (i.e. pigs and dogs) and in humans, due to a decrease in level of expression of defluorinating enzymes [31] . An alternative approach to decrease defluorination in a second-generation tracer would be to radiolabel at the ω-3 position of the acyl chain. Additionally, carbon-11 labeling of the dodecanoyl chain could be accomplished similar to 11 C-palmitate [37, 38] . Another approach to decrease the magnitude of systemic defluorination could involve pre-treatment with miconazole (CYP450 2E1 inhibitor) which was shown effective for 18 F-FCWAY [39] , which, however, is not practical for clinical translation because of potential for high patient to patient variability. Further radiotracer development is underway and will be reported elsewhere.
SIRT2 is an emerging target for therapy of various neurologic diseases, including neurodegeneration [10] , as well as cardiac [40] and metabolic diseases [40, 41] . Many SIRT2-targeted inhibitors are currently in development and entering the early-stage clinical trials, further driving the need for continuation of this work towards development and clinical translation of second-generation SIRT2-selective radiotracer.
Conclusions
In summary, guided by the results of biochemical and in silico modeling studies of structure-activity relationships between SIRT2 and a peptide-mimetic backbone containing a lysine derivatized with fluoroalkyl chains of different length, we have developed and tested in vitro and in vivo a novel, first-generation, SIRT2-selective substrate-type radiotracer, 12-[
18 F]DDAHA. Current proof of principal studies, demonstrated suitability for radiofluorinated DDAHA assessment of SIRT2 expression-activity using in vitro radiotracer uptake assays. Molecular imaging with PET using next-generation SIRT2-specific radiofluorinated DDAHAbased radiotracer, which is resistant to defluorination in vivo, should provide valuable information about the location and magnitude of SIRT2 expression and activity in the brain and in tumors. PET imaging may help to determine the mechanistic, therapeutic, and prognostic roles of SIRT2 in different diseases and enable monitoring of SIRT2 targeted therapies.
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